Gilead Announces 24-Week Results from Phase II Study of Investigational HIV Integrase Inhibitor GS 9137
Gilead Sciences, Inc. announced 24-week data from a Phase II clinical trial evaluating three doses of GS 9137 (elvitegravir), a novel oral HIV integrase inhibitor. According to the company, the data show statistically superior reductions in viral load among HIV-positive treatment-experienced patients receiving 125 mg of once-daily GS 9137 boosted with 100 mg of ritonavir, compared to those receiving a boosted protease inhibitor, both in combination with an optimized background regimen.
"Integrase inhibitors represent a promising new class in the field of HIV treatment, and I am encouraged by these Phase II data for once-daily GS 9137," said Dr. Zolopa. "As a clinician, I am frequently reminded of the importance of expanding simplified treatment options for people living with HIV, particularly among treatment-experienced patients who have developed resistance to many existing medications."
Integrase inhibitors are an investigational class of antiretrovirals that interfere with HIV replication by blocking the ability of the virus to integrate into the genetic material of human cells. Novel classes of HIV-fighting drugs are needed as patients live longer and exhaust currently available treatment options.
Other news from the department research and development
